Neurothera Labs Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Revenue	0.68	0.86	1.31
Revenue Growth	-	-34.46%	-
Cost of Revenue	0.2	0.23	0.8
Gross Profit	0.48	0.63	0.51
Selling, General & Admin	2.5	1.57	1.6
Research & Development	1.83	1.8	1.71
Operating Expenses	4.33	3.37	3.31
Operating Income	-3.85	-2.74	-2.81
Interest Expense	-0.17	-0.13	-
Interest & Investment Income	0.13	0.04	0.02
Other Non Operating Income (Expenses)	-1.41	-1.41	-
EBT Excluding Unusual Items	-5.29	-4.23	-2.78
Asset Writedown	-0.12	-0.12	-1.34
Pretax Income	-5.41	-4.34	-4.13
Income Tax Expense	0.02	0.02	-
Earnings From Continuing Operations	-5.43	-4.36	-4.13
Minority Interest in Earnings	0.22	0.24	1.19
Net Income	-5.2	-4.12	-2.94
Net Income to Common	-5.2	-4.12	-2.94
Net Income Growth	-	-	-
Shares Outstanding (Basic)	6	5	5
Shares Outstanding (Diluted)	6	5	5
Shares Change	-	6.54%	-
EPS (Basic)	-0.88	-0.86	-0.65
EPS (Diluted)	-0.88	-0.86	-0.65
EPS Growth	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Gross Margin	71.18%	73.72%	38.74%
Operating Margin	-565.44%	-319.74%	-214.78%
Profit Margin	-765.15%	-481.66%	-225.27%
EBITDA	-3.66	-2.54	-2.44
EBITDA Margin	-	-297.08%	-186.75%
D&A For EBITDA	0.18	0.19	0.37
EBIT	-3.85	-2.74	-2.81
EBIT Margin	-	-	-214.78%
Advertising Expenses	-	0.16	0.37